Drug Payment Experiments Coming To Medicare, Medicaid

Centers For Medicare and Medicaid Services releases 'request for information' on how to approach development of new payment models for prescription drugs in government-sponsored insurance.

Money Wave

The Trump Administration will explore new payment models for prescription drugs at the Center for Medicare and Medicaid Innovation (CMMI) as part of a plan to redirect the focus of the reimbursement laboratory.

The Centers for Medicare and Medicaid Services released a "request for information" Sept. 20 seeking public comments on...

More from Government Payers

Biktarvy, Trikafta Affected As Medicaid Cuts Could Increase Patient Assistance Demands

 
• By 

Patient access to mental health drugs also will be challenged by the policies in the new budget reconciliation legislation.

33 States Agree To Standardized Access Policies In Medicaid Sickle Cell Payment Demo

 

States also agreed to fund patient travel to specialized treatment centers as part of their participation in the Medicaid demo of CMS-negotiated outcomes-based contracts for Vertex/CRISPR's Casgevy and bluebird bio's Lyfgenia.

Part B Negotiation Proposal Would Lower Prices In MA, Private Plans Too, Stakeholders Complain

 
• By 

The issue is attracting more attention as the 2028 deadline for implementing Medicare negotiated prices for Part B drugs approaches.

China Unveils Multiple Policies To Support Innovative Drugs Throughout Life Cycle

 
• By 

China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.

More from Market Access